Astellas buys Xyphos – and its cell therapy platform – for $665M
The deal comes less than a month after the Japanese drugmaker said it would spend $3 billion to acquire gene therapy developer Audentes Therapeutics.
Xyphos Biosciences
The deal comes less than a month after the Japanese drugmaker said it would spend $3 billion to acquire gene therapy developer Audentes Therapeutics.